Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Accounting Title	2017/03/31	2016/12/31	2016/03/31
Balance Sheet			
Current assets			
Total cash and cash equivalents	210,339	309,771	458,00
Total Current investments in debt instrument without active market	448,871	455,399	610,82
Accounts receivable, net	17,536	23,328	5,57
Accounts receivable due from related parties, net	289	24,472	3
Other receivables, net	5,313	2,838	12,38
Total current tax assets	1,973	1,907	4,21
Total inventories	54,686	50,395	24,43
Total prepayments	22,185	19,989	33,83
Total other current assets	48,586	48,402	10,03
Total current assets	809,778	936,501	1,159,32
Non-current assets			
Non-current financial assets at cost, net	20,000	20,000	
Total Non-current investments in debt instrument without active market	0	30,000	30,00
Total property, plant and equipment	351,545	315,000	216,57
Total intangible assets	2,108	2,342	36
Deferred tax assets	39,027	39,599	39,67
Total other non-current assets	86,400	45,906	16,01
Total non-current assets	499,080	452,847	302,62
Total assets	1,308,858	1,389,348	1,461,95
Current liabilities			
Total accounts payable	20,737	22,069	17,78
Total other payables	29,603	42,658	24,28
Other payables to related parties	0	6	
Total other current liabilities	6,544	5,728	20,90
Total current liabilities	56,884	70,461	62,97
Non-current liabilities			
Total deferred tax liabilities	0	473	36
Total other non-current liabilities	2,256	2,271	1,72
Total non-current liabilities	2,256	2,744	2,08
Total liabilities	59,140	73,205	65,06
Share capital			
Ordinary share	1,120,445	1,120,005	1,117,15
Advance receipts for share capital	814	807	1,98
Total share capital	1,121,259	1,120,812	1,119,13
Capital surplus			
Total capital surplus, additional paid-in capital	621,871	621,104	616,54
Capital surplus, treasury share transactions	2,812	2,812	2,81
Capital surplus, employee share options	20,813	15,695	3,62
Total capital surplus	645,496	639,611	622,96
Retained earnings			
Total unappropriated retained earnings (accumulated deficit)	-429,426	-356,669	-257,59
Total retained earnings	-429,426	-356,669	-257,59
Other equity interest			
Total other equity, others	0	0	
Total other equity interest	0	0	
Treasury shares	-87,611	-87,611	-87,6
Total equity	1,249,718	1,316,143	1,396,89
Total liabilities and equity	1,308,858	1,389,348	1,461,95
Number of share capital awaiting retirement	0	0	
Equivalent issue shares of advance receipts for ordinary share	44,000	44,000	103,00
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000	2,200,00

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Accounting Title	2017/01/01To2017/03/31	2016/01/01To2016/03/31		
Income Statement	· · ·			
Total operating revenue	25,234	9,969		
Total operating costs	40,633	30,657		
Gross profit (loss) from operations	-15,399	-20,688		
Gross profit (loss) from operations	-15,399	-20,688		
Operating expenses				
Total selling expenses	1,947	2,085		
Total administrative expenses	11,023	7,078		
Total research and development expenses	40,106	41,076		
Total operating expenses	53,076	50,239		
Net operating income (loss)	-68,475	-70,92		
Non-operating income and expenses				
Total other income	6,290	13,371		
Other gains and losses, net	-10,473	-2,2		
Total non-operating income and expenses	-4,183	11,092		
Profit (loss) from continuing operations before tax	-72,658	-59,8		
Total tax expense (income)	99			
Profit (loss) from continuing operations	-72,757	-59,900		
Profit (loss)	-72,757	-59,900		
Total comprehensive income	-72,757	-59,900		
Basic earnings per share				
Total basic earnings per share	-0.66	-0.55		

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Accounting Title	2017/01/01To2017/03/31	2016/01/01To2016/03/31
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-72,658	-59,835
Profit (loss) before tax	-72,658	-59,835
Depreciation expense	13,348	9,454
Amortization expense	234	212
Provision (reversal of provision) for bad debt expense	39	3
Interest income	-1,278	-2,452
Share-based payments	5,518	595
Loss (gain) on disposal of property, plan and equipment	-112	(
Impairment loss on non-financial assets	179	22
Total adjustments to reconcile profit (loss)	17,928	7,834
Decrease (increase) in notes receivable due from related parties	0	71
Decrease (increase) in accounts receivable	5,753	12,992
Decrease (increase) in accounts receivable due from related parties	24,183	-30
Decrease (increase) in other receivable	-2,389	-9,654
Decrease (increase) in other receivable due from related parties	2,000	0,00
Decrease (increase) in inventories	-4,470	-1,828
Decrease (increase) in prepayments	-2,196	-12,257
Decrease (increase) in other current assets	-184	-708
Total changes in operating assets	20,697	-11,414
Increase (decrease) in notes payable	20,037	- 11,414
Increase (decrease) in accounts payable	-1,332	-1,834
Increase (decrease) in accounts payable to related parties	-1,352	-1,83-
Increase (decrease) in accounts payable to related parties	-11,554	-10,917
Increase (decrease) in other payable to related parties	-11,354	-10,917
Increase (decrease) in other current liabilities	816	9,284
Increase (decrease) in other current habilities	-15	9,204
	-13 -12,091	
Total changes in operating liabilities Total changes in operating assets and liabilities		
Total adjustments	8,606	-14,929
·	26,534	-7,095
Cash inflow (outflow) generated from operations	-46,124	-66,930
Income taxes refund (paid)	-66	-174
Net cash flows from (used in) operating activities	-46,190	-67,104
Cash flows from (used in) investing activities	00.000	70.000
Acquisition of investments in debt instrument without active market	-32,639	-72,668
Proceeds from disposal of investments in debt instrument without active market	69,167	321,709
Increase in prepayments for investments	-67,000	
Acquisition of property, plant and equipment	-10,926	-21,243
Increase in refundable deposits	0	-171
Acquisition of intangible assets	0	(
Increase in prepayments for business facilities	-13,964	-12,737
Interest received	1,306	2,618
Net cash flows from (used in) investing activities	-54,056	217,508
Cash flows from (used in) financing activities		
Exercise of employee share options	814	1,983
Net cash flows from (used in) financing activities	814	1,983
Effect of exchange rate changes on cash and cash equivalents	0	(
Net increase (decrease) in cash and cash equivalents	-99,432	152,387
Cash and cash equivalents at beginning of period	309,771	305,619
Cash and cash equivalents at end of period	210,339	458,006
Cash and cash equivalents reported in the statement of financial position	210,339	458,006
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	C

Financial Statement – Statements of Changes in Stockholders' Equity

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

											2017/0	3/31 Statement of Stockholders Equi	Ly						
										U	Unit: NT\$ thousand								
Accounting Title	Ordinary share Advance	ance receipts for share capital Total	al share capital Capital surplu	lus Unappropriated retained earnings (accumulated	ed deficit) Total retaine	ed earnings Exchange differences	on translation of foreign financial statemen	ts Gains (losses) from investments in equ	quity instruments measured at fair value through other comprehe			ion of cash flow hedges Gains (losses) on effective portion of	hedges of net investments in foreign operations Change in fair value of financial liability at	ttributable to change in credit risk of liability Gains (losses) on remea	asurements of defined benefit Revaluation s	surplus Equity related to non-current assets classified as h	eld for sale Others Total othe	her equity interest Treasury s	shares Total equi
uity at end of period	1,120,005	807	1,120,812 639,67	11 د	-356,669	-356,669		0		0	0	0	0	0	0	0	0 0	0 -4	-87,611 1,316,1
Equity at beginning of period after adjustment	s 1,120,005	807	1,120,812 639,6	11	-356,669	-356,669		0		0	0	0	0	0	0	0	0 0	0 -4	-87,611 1,316,1
ofit (loss)	0	0	0	0	-72,757	-72,757		0		0	0	0	0	0	0	0	0 0	0	0 -72,
ther comprehensive income	0	0	0	0	0	0		0		0	0	0	0	0	0	0	0 0	0	0
tal comprehensive income	0	0	0	0	-72,757	-72,757		0		0	0	0	0	0	0	0	0 0	0	0 -72,
are-based payments tal increase (decrease) in equity juity at end of period	440	7	447 5,8	.85	0	0		0		0	0	0	0	0	0	0	0 0	0	0 6,3
tal increase (decrease) in equity	440	7	447 5,8'	.85	-72,757	-72,757		0		0	0	0	0	0	0	0	0 0	0	0 -66,4
≟quity at end of period	1,120,445	814	1,121,259 645,49	+96	-429,426	-429,426		0		0	0	0	0	0	0	0	0 0	0	-87,611 1,249,7
										2016/03/31 State	ement of Stockholders' Equity								
		Acco	unting Title	tinary share Advance receipts for share canital To	tal share canital Can	nital surplus I Inannronriated retain	accumulated deficit) Total reta	ained earnings Exchange differences on t	translation of foreign financial statements (Cains (Josses) from in		ement of Stockholders' Equity Unit: NT\$ thousand	se (Inesaes) na available_for.cale financial accete Gaine (Inesaes) on effective portion of cash flow hadree (Cains (Josses) on effective portion of hadres of	f net investments in foreign operations Equity related to non-current	assats classified as hald for sale Others Tot	ntal other equity interest Treasury shares Total equity			
			counting Title Ord	Ordinary share Advance receipts for share capital To	Fotal share capital Cap	pital surplus Unappropriated retain	ned earnings (accumulated deficit) Total reta	ained earnings Exchange differences on t	translation of foreign financial statements Gains (losses) from in			ns (losses) on available-for-sale financial assets Gains (losses) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of	f net investments in foreign operations Equity related to non-current	assets classified as held for sale Others Tot	otal other equity interest Treasury shares Total equity			
		Equity at end of pe	period	rdinary share Advance receipts for share capital Tc 1,115,990 2,211 1,115,990 2,211	otal share capital Car 1,118,201 1,118,201	pital surplus Unappropriated retain 621,319 621,319	ned earnings (accumulated deficit) -197,695 -197,695	ained earnings Exchange differences on t -197,695 -197,695	translation of foreign financial statements Gains (losses) from ir 0			is (losses) on available-for-sale financial assets Gains (losses 0 0) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of 0	f net investments in foreign operations Equity related to non-current 0 0	assets classified as held for sale Others Tot	otal other equity interest Treasury shares Total equity 0 -87,611 1,454,214 0 -87,611 1,454,214			
		Equity at end of pe	3	rdinary share Advance receipts for share capital Tr 1,115,990 2,211 1,115,990 2,211 0 0	otal share capital Caj 1,118,201 1,118,201 0	pital surplus Unappropriated retain 621,319 621,319 0	ned earnings (accumulated deficit) Total reta -197,695 -197,695 -59,900	ained earnings Exchange differences on t -197,695 -197,695 -59,900	translation of foreign financial statements Gains (losses) from ir 0 0			ns (losses) on available-for-sale financial assets Gains (losses 0 0 0) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of 0 0	f net investments in foreign operations Equity related to non-current 0 0 0	assets classified as held for sale Others Tot 0 0 0 0 0 0	0 -87,611 1,454,214 0 -87,611 1,454,214 0 -87,611 1,454,214 0 0 -87,611 1,454,214			
		Equity at end of pe Equity at beginning Profit (loss)	period ing of period after adjustments	rdinary share Advance receipts for share capital Tr 1,115,990 2,211 1,115,990 2,211 0 0 0	otal share capital Cai 1,118,201 1,118,201 0 0	pital surplus Unappropriated retain 621,319 621,319 0 0	ned earnings (accumulated deficit) Total reta -197,695 -197,695 -59,900 0	ained earnings Exchange differences on t -197,695 -197,695 -59,900 0	translation of foreign financial statements Gains (losses) from in 0 0 0 0			us (losses) on available-for-sale financial assets Gains (losses 0 0 0 0 0) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of 0 0 0 0	f net investments in foreign operations Equity related to non-current 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	assets classified as held for sale Others Tot 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	otal other equity interest Treasury shares Total equity 0 -87,611 1,454,214 0 -87,611 1,454,214 0 0 -59,900 0 0 0			
		Equity at end of pe Equity at beginning Profit (loss) Other comprehens Total comprehensi	ng of period after adjustments nsive income sive income	rdinary share Advance receipts for share capital Tr 1,115,990 2,211 1,115,990 2,211 0 0 0 0 0 0 0 0 0 0	otal share capital Ca _l 1,118,201 1,118,201 0 0 0 0	pital surplus Unappropriated retain 621,319 621,319 0 0 0 0	ned earnings (accumulated deficit) -197,695 -197,695 -59,900 0 -59,900	ained earnings Exchange differences on t -197,695 -197,695 -59,900 0 -59,900	translation of foreign financial statements Gains (losses) from in 0 0 0 0 0 0			ns (losses) on available-for-sale financial assets Gains (losses 0 0 0 0 0 0) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of 0 0 0 0 0	f net investments in foreign operations Equity related to non-current 0 0 0 0 0 0 0 0 0 0 0 0	assets classified as held for sale Others Tot 0 0 0 0 0 0 0 0 0 0	otal other equity interest Treasury shares Total equity 0 -87,611 1,454,214 0 -87,611 1,454,214 0 0 -59,900 0 0 0 0 0 0 0 0 0			
		Equity at end of pe Equity at beginning Profit (loss) Other comprehens Total comprehensi	ng of period after adjustments nsive income sive income	rdinary share Advance receipts for share capital Ti 1,115,990 2,211 1,115,990 2,211 0 0 0 0 0 0 0 1,160 -228	1,118,201 1,118,201 0 0 0 0 932	621,319 621,319 0 0 0 1 646	ned earnings (accumulated deficit) Total reta -197,695 -197,695 -59,900 0 -59,900 0 0	ained earnings Exchange differences on t -197,695 -197,695 -59,900 0 -59,900 0 0	translation of foreign financial statements Gains (losses) from in 0 0 0 0 0 0 0			us (losses) on available-for-sale financial assets Gains (losses 0 0 0 0 0 0 0 0 0) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of 0 0 0 0 0 0 0 0	f net investments in foreign operations Equity related to non-current 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	assets classified as held for sale Others Tot 0 0 0 0 0 0 0 0 0 0 0 0	otal other equity interest Treasury shares Total equity 0 -87,611 1,454,214 0 -87,611 1,454,214 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,578			
		Equity at end of pe Equity at beginning Profit (loss) Other comprehensi Total comprehensi Share-based paym	period after adjustments nsive income sive income ments ecrease) in equity	rdinary share Advance receipts for share capital Tr 1,115,990 2,211 1,115,990 2,211 0 0 0 0 0 0 0 1,160 -228 1,160 -228	1,118,201 1,118,201 0 0 0 0 932	pital surplus Unappropriated retain 621,319 0 0 0 0 1,646 1,646	ned earnings (accumulated deficit) Total reta -197,695 -59,900 0 -59,900 0 -59,900 0 -59,900 0 -59,900	ained earnings Exchange differences on t -197,695 -197,695 -59,900 0 -59,900 0 -59,900 0 -59,900	translation of foreign financial statements Gains (losses) from in 0 0 0 0 0 0 0 0 0 0			ns (losses) on available-for-sale financial assets Gains (losses 0 0 0 0 0 0 0 0 0 0 0) on effective portion of cash flow hedges Gains (losses) on effective portion of hedges of 0 0 0 0 0 0 0 0 0	f net investments in foreign operations Equity related to non-current 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	assets classified as held for sale Others Tot 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	O -87,611 1,454,214 0 -87,611 1,454,214 0 -87,611 1,454,214 0 0 -85,900 0 0 0 0 0 -95,900 0 0 -59,900 0 0 2,578 0 0 -57,322			

						Unit: NT\$ the	ousand								
ots for share capital Total share capital Cap	ital surplus Unappropriated ret	ained earnings (accumulated deficit) Total re	etained earnings Exchange di	ifferences on translation of foreign financial stat	atements Gains (losses	s) from investments in equity instruments measured at fair value through other comprehensive income Unrealized gains (losses) on available-for-sale finan	cial assets Gains (losses) on effective portion of cash flow he	edges Gains (losses) on effective portion of hedges of net investments in foreign operation	ns Change in fair value of financial liability attributable to change in credit risk of liab	ility Gains (losses) on remeasurements of defined benefit Reva	uation surplus Equity related	to non-current assets classified as hel	d for sale Others Total other	r equity interest Treas	ury shares Total equity
807 1,120,812	639,611	-356,669	-356,669		0	0	0	0	0	0 0	0		0 0	0	-87,611 1,316,143
807 1,120,812	639,611	-356,669	-356,669		0	0	0	0	0	0 0	0		0 0	0	-87,611 1,316,143
0 0	0	-72,757	-72,757		0	0	0	0	0	0 0	0		0 0	0	0 -72,757
0 0	0	0	0		0	0	0	0	0	0 0	0		0 0	0	0 0
0 0	0	-72,757	-72,757		0	0	0	0	0	0 0	0		0 0	0	0 -72,757
7 447	5,885	0	0		0	0	0	0	0	0 0	0		0 0	0	0 6,332
7 447	5,885	-72,757	-72,757		0	0	0	0	0	00	0		0 0	0	0 -66,425
814 1,121,259	645,496	-429,426	-429,426		0	0	0	0	0	0 0	0		0 0	0	-87,611 1,249,718
Accounting Title	Ordinary share Advance	receipts for share capital Total share capital	al Capital surplus Unappropria	ated retained earnings (accumulated deficit) Tot	tal retained earnings	2016/03/31 Statement of Unit: NT\$ the Exchange differences on translation of foreign financial statements Gains (losses) from investments in equity instruments measured at fair value through ot	her comprehensive income Unrealized gains (losses) on avai	ilable-for-sale financial assets Gains (losses) on effective portion of cash flow hedges Gai	ins (losses) on effective portion of hedges of net investments in foreign operations E	Equity related to non-current assets classified as held for sale C	hers Total other equity interes	st Treasury shares Total equity			
Equity at end of period	1,115,990	2,211 1,118,201	1 621,319	-197,695	-197,695	0	0	0 0	0	0	0	0 -87,611 1,454,214			
Equity at beginning of period after adjust	tments 1,115,990	2,211 1,118,201	1 621,319	-197,695	-197,695	0	0	0 0	0	0	0	0 -87,611 1,454,214			
Profit (loss)	0	0 0	0 0	-59,900	-59,900	0	0	0 0	0	0	0	0 0 -59,900			
Other comprehensive income	0	0 0	0 0	0	0	0	0	0 0	0	0	0	0 0 0			
Total comprehensive income	0	0 0	0 0	-59,900	-59,900	0	0	0 0	0	0	0	0 0 -59,900			
Share-based payments	1,160	-228 932	2 1,646	0	0	0	0	0 0	0	0	0	0 0 2,578			
Equity at end of period Equity at beginning of period after adjust Profit (loss) Other comprehensive income Total comprehensive income Share-based payments Total increase (decrease) in equity	1,160	-228 932	2 1,646	-59,900	-59,900	0	0	00	0	0	0	0 0 -57,322			
Equity at end of period	1,117,150	1,983 1,119,133	3 622,965	-257,595	-257,595	0	0	0 0	0	0	0	0 -87,611 1,396,892			

2017/03/31 Statement of Stockholders' Equity

Back>>